title: Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS.
abstract: A randomized study of 12 treated patients and seven controls was conducted in order to evaluate HPA-23 anti-HIV activity in HIV-infected patients. The antiviral activity was assessed by determining HIV p24 antigenemia. A persistence or even increase in antigenemia was shown in treated patients and thrombocytopenia was observed in nine out of the 12 patients. This suggests that HPA-23 should not be used in anti-HIV therapy.
authors: Laboratoire de Microbiologie, Hôpital Necker, Paris, France.
authors: M
authors: M
authors: Burgard
authors: P
authors: P
authors: Sansonetti
authors: D
authors: D
authors: Vittecoq
authors: P
authors: P
authors: Descamps
authors: D
authors: D
authors: Guetard
authors: S
authors: S
authors: Herson
authors: W
authors: W
authors: Rozenbaum
authors: C
authors: C
authors: Rouzioux
mesh_terms: D000965:Antimony / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005500:Follow-Up Studies; D015683:Gene Products, gag / Q000097:blood*; D015488:HIV Antigens / Q000097:blood*; D016655:HIV Core Protein p24; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D010976:Platelet Count; D011897:Random Allocation; D018894:Reverse Transcriptase Inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced; D014414:Tungsten / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017973:Tungsten Compounds; D014758:Viral Core Proteins / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D015683:Gene Products, gag; D015488:HIV Antigens; D016655:HIV Core Protein p24; D018894:Reverse Transcriptase Inhibitors; D017973:Tungsten Compounds; D014758:Viral Core Proteins; C009613:ammonium tungsten antimonate hydroxide oxide; D000965:Antimony; D014414:Tungsten